PFE

$26.49

Public overview and default valuation.

Log in to track this stock.

Valuation Details
Default assumptions: 10Y forecast, 9% market return, 2.5% terminal growth, 1.10% trendline growth.
Want to create your own valuation? Create a free account.
$63.32

With 20% Margin of Safety (MoS):

$50.66
91.23% upside
Capital Efficiency
Average Quarterly ROIC
1.61%
Cost of Capital (estimated)9%
Value StatusUnderperforming Capital

The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.

Complete historical ROIC is available with
.
Fundamental Score
60
NeutralWeighted across 6 signals
DCF Discount
91.2% discount to price
100
FCF Yield
10.5% trailing FCF yield
100
ROIC vs WACC
ROIC 1.6% vs WACC 9.0% (0.2x)
9
Net Debt / FCF
Net cash position
100
Buybacks
Share count shrinking
80
FCF CAGR (5Y)
0.8% 5Y FCF CAGR
25
Strengths: DCF Discount, FCF Yield. Concerns: ROIC vs WACC, FCF CAGR (5Y).
Narrative Score
69
Improving
Weighted across 4 recent drivers · Last 30 days+1 vs previousVs 6-Month Baseline: Average (42th pct)
Trend: StableConfidence: 100%Updated: 3h ago
Sources: 206 (News 200 · Analyst 6)
Drivers
162 news sentiment+1.8
35 regulatory scrutiny+0.2
3 earnings beat-0.2
6 analyst reiterations0.0
Other Metrics
P/E14.9
Profit Margin15.6%
Owner Earnings$25.45b
One Dollar Premise68.00%
Debt/Equity1.32
Current Ratio1.22
PEG-1.762
Free Cash Flow (in millions)
20052006200720082009201020112012201320142015201620172018201920202021202220232024
$16,839$19,644$15,233$19,939$17,792$12,967$21,900$18,381$19,230$18,466$16,008$17,900$18,687$18,023$15,182$17,194$35,291$32,503$12,607$15,778
How Intrinziq Estimates Fair Value

Intrinziq estimates Pfizer Inc.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.

Pfizer Inc.Healthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Last updated: Feb 06, 2026
Data sources: Financial Modeling Prep
This valuation is based on assumptions and publicly available data. It is not financial advice or a recommendation to buy or sell any security. Always do your own research before making investment decisions.